Hepatitis Delta Franchise And T Cell Engagers Will Reshape Long Term Outlook

Catalysts

About Vir Biotechnology

Vir Biotechnology focuses on developing treatments that harness the immune system to address serious infectious diseases and cancer.

What are the underlying business or industry changes driving this perspective?

• Completion of enrollment in ECLIPSE 1 ahead of internal projections and strong momentum in ECLIPSE 2 and 3 point to an advanced, multi-study hepatitis delta franchise that, if successful, could convert a concentrated pool of approximately 61,000 RNA positive patients in the US and 113,000 in EU markets into a focused revenue stream supported by an efficient specialist sales model.
• Upcoming, closely spaced data readouts, including the comprehensive 48 week SOLSTICE data set and top line results from all three ECLIPSE studies targeted for early 2027, create a clear clinical and regulatory path that, if positive, could shift the company from primarily R&D driven spending toward a product revenue contribution that supports earnings over time.
• The PRO XTEN masked T cell engager platform now spans three active clinical programs, VIR 5500, VIR 5818 and VIR 5525, plus multiple preclinical candidates, so any favorable safety and efficacy profile in one target such as PSMA could be leveraged across HER2, EGFR and additional tumor antigens, increasing the potential addressable market and supporting a longer term revenue base.
• The focus on T cell engagers for solid tumors like metastatic castration resistant prostate cancer, with VIR 5500 progressing in late line patients and first line combination with androgen receptor pathway inhibitors underway, positions Vir in areas of substantial unmet need that, if data are supportive, could improve pricing power and gross margins relative to more crowded treatment categories.
• A cash, cash equivalents and investments balance of about US$810.7 million and an operating plan that currently extends the cash runway into mid 2027 allows Vir to fund its registrational hepatitis delta program and oncology trials without immediate external financing, helping manage dilution risk and providing flexibility to allocate capital toward programs that may have the greatest impact on future revenue and earnings.

Assumptions

This narrative explores a more optimistic perspective on Vir Biotechnology compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Vir Biotechnology's revenue will grow by 176.3% annually over the next 3 years.
• The bullish analysts are not forecasting that Vir Biotechnology will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Vir Biotechnology's profit margin will increase from -2963.5% to the average US Biotechs industry of 16.2% in 3 years.
• If Vir Biotechnology's profit margin were to converge on the industry average, you could expect earnings to reach $57.8 million (and earnings per share of $0.4) by about January 2029, up from $-499.7 million today.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 88.9x on those 2029 earnings, up from -1.7x today. This future PE is greater than the current PE for the US Biotechs industry at 21.5x.
• The bullish analysts expect the number of shares outstanding to grow by 1.45% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.23%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Vir Biotechnology remains loss making, with a third quarter 2025 net loss of US$163.1 million and operating expenses of US$173.7 million. If its hepatitis delta and oncology programs do not translate into meaningful commercial products, the company may need to cut spending, raise capital or accept shareholder dilution, which would weigh on future earnings and potentially constrain revenue growth.
• The investment case leans heavily on positive outcomes from the hepatitis delta ECLIPSE program and the SOLSTICE data set. Any weaker than expected efficacy, safety concerns or regulatory hurdles could limit uptake in the approximately 61,000 RNA positive patients in the US and 113,000 in EU markets, which would directly pressure long term revenue potential and delay any improvement in net margins.
• The oncology pipeline relies on the PRO XTEN masked T cell engager platform across multiple targets such as PSMA, HER2 and EGFR, yet these programs are still in early clinical stages with no maximum tolerated dose reached for VIR 5500 and no detailed safety or efficacy data disclosed. Platform setbacks or competitor therapies with better durability or tolerability could reduce pricing power and constrain future earnings.
• The company’s current cash, cash equivalents and investments of about US$810.7 million are projected to fund operations into mid 2027 based on the existing plan. If development timelines extend, additional studies are required or commercialization costs exceed expectations, Vir may need extra funding earlier than planned, which could negatively affect earnings per share and keep net margins deeply negative for longer.
• Management expects Gilead’s bulevirtide to be a positive catalyst for disease awareness. If bulevirtide at the higher 10 milligram dose secures strong physician adoption and payer support ahead of Vir’s launch, it could entrench treatment habits and compress Vir’s share of the hepatitis delta opportunity, limiting pricing flexibility and capping both peak revenue and the ability to improve margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Vir Biotechnology is $28.68, which represents up to two standard deviations above the consensus price target of $17.11. This valuation is based on what can be assumed as the expectations of Vir Biotechnology's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $31.0, and the most bearish reporting a price target of just $12.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $355.8 million, earnings will come to $57.8 million, and it would be trading on a PE ratio of 88.9x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $6.16, the analyst price target of $28.68 is 78.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.